Lilly turns to pain after solanezumab failure

With a new focus on pain and migraine medications, Eli Lilly hopes to reinvigorate its neuroscience pipeline and portfolio.

By Jacob Bell • Jan. 25, 2017

Why biosimilars could be market disruptors

The biologic copies are just now entering the U.S. market and could mean a shift in several major therapeutic indications. 

By Suzanne Elvidge • Jan. 23, 2017

Explore the Trendline➔

Neuroscience drug development

Enthusiasm is running higher among drugmakers and investors for neuroscience drug development, buoyed by recent approvals of new Alzheimer’s, ALS and depression medicines.

By BioPharma Dive staff

Marinus up on small ganaxolone hope

The Pennsylvania biotech reported positive data in a small number of patients, giving hope to investors. 

By Lisa LaMotta • Jan. 23, 2017

Actelion misses goal in study, but takeover talks likely unaffected

Pharma giant J&J is in exclusive discussions with Actelion about a potential acquisition of the Swiss biotech and its portfolio of drugs for pulmonary hypertension. 

By Ned Pagliarulo • Jan. 23, 2017

FDA gives go-ahead to Synergy's constipation drug

Facing a crowded market, the company’s CEO asserts that Synergy has “the right strategic vision and the right launch plan” for Trulance.

By Judy Packer-Tursman • Jan. 22, 2017

Prescribed Reading: A new era in pharma

Trump is in, Califf is out, Bristol-Myers foregoes any possible lead in lung cancer and the FDA made its mark. 

By Lisa LaMotta • Jan. 20, 2017

Neurocrine's Tourette drug misses mark in mid-stage trial

The company remains optimistic about the treatment's potential, pursuing other indications for it including tardive dyskinesia.  

By Jacob Bell • Jan. 19, 2017

AstraZeneca angles for more competitive position in I/O

Shifting the timeline and endpoints of the MYSTIC study could strengthen AstraZeneca's position in lung cancer. 

By Suzanne Elvidge • Jan. 18, 2017

Trial failure deals harsh blow to Alcobra

The company, which focuses on cognitive disorder treatments, said its only candidate missed the primary endpoint of a Phase 3 study testing the drug in patients with ADHD.

By Jacob Bell • Jan. 17, 2017

Biogen upbeat about new Spinraza data

Positive results for the company's newly approved spinal muscular atrophy drug could support its sky high price tag.

By Suzanne Elvidge • Jan. 17, 2017

Allergan moves toward NDA after uterine fibroid drug's success

The Irish biopharma expects to submit the drug, which is already marketed in Canada and Europe, for U.S. approval in the latter half of 2017.

By Jacob Bell • Jan. 17, 2017

Tesaro plans speedy response to CRL for nausea drug

The drugmaker disclosed last week the FDA had requested more details on manufacturing practices, an area where an increasing number of applications have fallen short. 

By Suzanne Elvidge • Jan. 13, 2017

Kite confident as CAR-T readout nears

The next two months will be crucial for Kite, which hopes to secure the first approval for a CAR-T therapy in the U.S. 

By Ned Pagliarulo • Jan. 12, 2017

NCI launches new cancer drug formulary to speed combo trials

As pharma dollars pour into oncology, interest in the potential for combination therapies has grown dramatically. 

By Ned Pagliarulo • Jan. 11, 2017

SCOPE 2017: Calling out Clinical Technology - Booth #400

As technology improves industries around us, drug development has gone the opposite direction with less efficient operations. 

Jan. 10, 2017

Prescribed Reading: Quiet before the storm

M&A was slow in 2016 and 2017 is off to a slow start. But the JP Morgan conference in San Francisco next week could put dealmaking back in full swing. 

By Lisa LaMotta • Jan. 6, 2017

Halozyme unveils mid-stage data for pancreatic cancer drug

The cancer-focused biotech said its drug has an edge in progression-free-survival, though some remain skeptical.

By Jacob Bell • Jan. 5, 2017

Ocular boasts more positive data for Dextenza

The company intends to release safety data and submit the post-surgery eye inflammation drug for approval in early 2017.

By Jacob Bell • Jan. 5, 2017

Inotek shares freefall after glaucoma drug failure

The Lexington, MA-based company's shares were 71% lower on Tuesday than when the markets closed on Dec. 30.

By Jacob Bell • Jan. 4, 2017

Newron sees promise in schizophrenia drug

Preliminary Phase 2a results showed the drug was generally well-tolerated, leading the company to believe further testing is warranted.

By Suzanne Elvidge • Jan. 4, 2017

As R&D returns take a hit, some pharmas are ramping up spending

BioPharma Dive will be publishing several articles in the coming weeks taking a look at the numbers behind R&D spending and drug revenues. 

By Ned Pagliarulo • Dec. 24, 2016

Prescribed Reading: An uptick in year-end M&A

Several companies are striking deals to round out the year, while others are trying to bury bad data, and the FDA cracks down on manufacturing. 

By Lisa LaMotta • Dec. 23, 2016

Roche hemophilia drug hits mark in Phase 3

The Swiss pharma also offered up more details on four adverse events which had sparked concerns about the drug's prospects last month. 

By Suzanne Elvidge • Dec. 23, 2016

Roche touts efficacy of MS drug despite delays

More complete data on the safety and efficacy of Ocrevus was published this week in The New England Journal of Medicine. 

By Suzanne Elvidge • Dec. 23, 2016

Alexion fails to PROTECT Soliris franchise

A trial failure for the blockbuster drug adds to the string of bad news for the company. 

By Lisa LaMotta • Dec. 22, 2016